Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for B2W0S3
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-B2W0S3-F1 | Predicted | AlphaFoldDB |
No variants for B2W0S3
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for B2W0S3 | |||||
2 associated diseases with B2W0S3
[MIM: 608971]: Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID)
A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by variants affecting the gene represented in this entry.
[MIM: 126200]: Multiple sclerosis (MS)
A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.
Without disease ID
- A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by variants affecting the gene represented in this entry.
- A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.
10 regional properties for B2W0S3
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Tyrosine-specific protein phosphatase, PTPase domain | 652 - 914 | IPR000242-1 |
| domain | Tyrosine-specific protein phosphatase, PTPase domain | 943 - 1230 | IPR000242-2 |
| domain | Tyrosine-specific protein phosphatases domain | 832 - 903 | IPR000387-1 |
| domain | Tyrosine-specific protein phosphatases domain | 1135 - 1219 | IPR000387-2 |
| domain | Protein-tyrosine phosphatase, catalytic | 810 - 911 | IPR003595-1 |
| domain | Protein-tyrosine phosphatase, catalytic | 1116 - 1227 | IPR003595-2 |
| domain | Fibronectin type III | 391 - 483 | IPR003961-1 |
| domain | Fibronectin type III | 484 - 576 | IPR003961-2 |
| active_site | Protein-tyrosine phosphatase, active site | 851 - 861 | IPR016130 |
| domain | Protein tyrosine phosphatase, receptor type, N-terminal | 7 - 32 | IPR024739 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| vacuolar membrane | The lipid bilayer surrounding the vacuole and separating its contents from the cytoplasm of the cell. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| metal ion binding | Binding to a metal ion. |
| metalloexopeptidase activity | Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. |
1 GO annotations of biological process
| Name | Definition |
|---|---|
| proteolysis | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. |
No homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| No homologous proteins | ||||
| 10 | 20 | 30 | 40 | 50 | 60 |
| MARYNPFSFT | PGPVVFFTTV | IYVGLFAALL | VTHLTVPDYP | SDPPAGINLT | EAWADLEHIT |
| 70 | 80 | 90 | 100 | 110 | 120 |
| RRFHPYNSHA | NDHVRGYLLS | RIQGVIATKA | LDASQVEVID | DLTSNATFSS | GATSVYFEGT |
| 130 | 140 | 150 | 160 | 170 | 180 |
| NIIVVIRGSE | DDEPFNSTDR | KPNNGGVLVN | AHYDSVSSGY | GATDDGVGVV | TVLQLLSYFT |
| 190 | 200 | 210 | 220 | 230 | 240 |
| ESHNWPKRTI | ILLLNNGEED | FLNGAKAFMR | NPISQVPHTF | VNLEGAGAGG | RATLFRSTDT |
| 250 | 260 | 270 | 280 | 290 | 300 |
| EVTRFYSKSK | YPFGTVVSGD | GFKKGLIRSE | TDYRVFHGEL | GLRGLDIAFM | EPRARYHTVE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| DSTRETSMNS | LWHMLSAALA | STSGLAAVTG | EEFSGSESLD | NGRVNAGRGS | DGVWFDLFGR |
| 370 | 380 | 390 | 400 | 410 | 420 |
| VFVVFQLHTL | FALCVTLLVV | APIALIGLTF | GLSKADKNYL | LARKAFVYSS | DDDNPVQLYG |
| 430 | 440 | 450 | 460 | 470 | 480 |
| WRGFFRFPIV | FVSATAVVVA | LAYLLVRFNA | FIIYSSPFAV | WSMMLSAWFF | VAWFFSRGAD |
| 490 | 500 | 510 | 520 | 530 | 540 |
| AMRPSALQRM | YALIWLFIGS | FVLLTIITVF | VNNYQVVAGY | PALFYFAVVF | AALMLSYLEL |
| 550 | 560 | 570 | 580 | 590 | 600 |
| FFAPTKSAYA | RHFEHDTSSR | RNSESASRPL | TGSTTAARSD | DRPVADDDAT | ETTSLLRGDR |
| 610 | 620 | 630 | 640 | 650 | 660 |
| RGFTRYGSRR | DSTSEGDEDH | AQGSRRLDLG | NVYPGEQEWS | GKLPSWIWII | QLLLLAPLVI |
| 670 | 680 | 690 | 700 | 710 | 720 |
| VLVGQVALLL | TSALYQTPSD | GNSPLFIYLA | IAALSVLLLA | PTGPFIHRFT | YHVPTFLFLV |
| 730 | 740 | 750 | 760 | 770 | 780 |
| CLATVIYNLV | AFPFSRDHRL | KVYFVQRVNC | ETGANTVSLT | GLDSYVQRIV | GELPSAQDQP |
| 790 | 800 | 810 | 820 | 830 | 840 |
| LNCTTPDVAT | RKELKTCEWE | GLPAKVVPNA | AGAAPFGNET | NTDRWLEYSI | HKGNRSNKAT |
| 850 | 860 | 870 | 880 | 890 | 900 |
| IRVVGLNTRA | CRIVFDSPIT | GLAVTGAVSD | PRFKPVGAAG | SREVRLWHRE | FGQPWNVALT |
| 910 | 920 | 930 | 940 | 950 | |
| WDAEEHAKLS | GRVVCLWSDA | NTGSIPAFDE | VQHYLPVWAI | PSKISDGLVE | GFKQFEI |